Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Kruithof

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Journal of Gastroenterology and Hepatology|July 1, 1994
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancerG Webb, M S Baker, J Nicholl, et al.
Annals of the Rheumatic Diseases|September 25, 2004
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathyE Kruithof, D Baeten, F Van den Bosch, et al.
Annals of the Rheumatic Diseases|January 15, 2004
Case Number 29: Ochronosis: synovial histopathological characteristicsE Kruithof, D Baeten, E M Veys, et al.
Clinical Rheumatology|February 24, 2001
Polyarteritis nodosa mimicking polymyalgia rheumaticaE Kruithof, D Elewaut, J M Naeyaert, et al.
Lupus|January 24, 2006
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implicationsL De Rycke, D Baeten, E Kruithof, et al.
Annals of the Rheumatic Diseases|February 7, 2002
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow upE Kruithof, F Van den Bosch, D Baeten, et al.
Annals of the Rheumatic Diseases|April 18, 2002
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitisE Kruithof, P Kestelyn, C Elewaut, et al.
Annals of the Rheumatic Diseases|May 29, 2004
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritisL De Rycke, X Verhelst, E Kruithof, et al.
Annals of the Rheumatic Diseases|July 17, 2001
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalphaD Baeten, N Van Damme, F Van den Bosch, et al.
Annals of the Rheumatic Diseases|August 19, 2003
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?D Baeten, E Kruithof, F Van den Bosch, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Journal of Gastroenterology and Hepatology|July 1, 1994
Chromosomal localization of the human urokinase plasminogen activator receptor and plasminogen activator inhibitor type-2 genes: implications in colorectal cancerG Webb, M S Baker, J Nicholl, et al.
Annals of the Rheumatic Diseases|September 25, 2004
Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathyE Kruithof, D Baeten, F Van den Bosch, et al.
Annals of the Rheumatic Diseases|January 15, 2004
Case Number 29: Ochronosis: synovial histopathological characteristicsE Kruithof, D Baeten, E M Veys, et al.
Clinical Rheumatology|February 24, 2001
Polyarteritis nodosa mimicking polymyalgia rheumaticaE Kruithof, D Elewaut, J M Naeyaert, et al.
Lupus|January 24, 2006
The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implicationsL De Rycke, D Baeten, E Kruithof, et al.
Annals of the Rheumatic Diseases|February 7, 2002
Repeated infusions of infliximab, a chimeric anti-TNFalpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow upE Kruithof, F Van den Bosch, D Baeten, et al.
Annals of the Rheumatic Diseases|April 18, 2002
Successful use of infliximab in a patient with treatment resistant spondyloarthropathy related uveitisE Kruithof, P Kestelyn, C Elewaut, et al.
Annals of the Rheumatic Diseases|May 29, 2004
Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritisL De Rycke, X Verhelst, E Kruithof, et al.
Annals of the Rheumatic Diseases|July 17, 2001
Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalphaD Baeten, N Van Damme, F Van den Bosch, et al.
Annals of the Rheumatic Diseases|August 19, 2003
Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?D Baeten, E Kruithof, F Van den Bosch, et al.
Pageof 3